Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 2000, p. 2133-2142, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Analysis of rdxA and Involvement of Additional Genes
Encoding NAD(P)H Flavin Oxidoreductase (FrxA) and Ferredoxin-Like
Protein (FdxB) in Metronidazole Resistance of Helicobacter
pylori
Dong-Hyeon
Kwon,1,*
Fouad A. K.
El-Zaatari,1,2
Mototsugu
Kato,1
Michael S.
Osato,1
Rita
Reddy,1
Yoshio
Yamaoka,1 and
David Y.
Graham1,2,3
Department of
Medicine1 and Division of Molecular
Virology,3 Baylor College of Medicine, and
Inflammatory Bowel Disease Laboratory, Veterans Affairs Medical
Center,2 Houston, Texas 77030
Received 18 November 1999/Returned for modification 19 March
2000/Accepted 8 May 2000
 |
ABSTRACT |
Metronidazole (Mtz) is a critical ingredient of modern multidrug
therapies for Helicobacter pylori infection. Mtz resistance reduces the effectiveness of these combinations. Although null mutations in a rdxA gene that encodes oxygen-insensitive
NAD(P)H nitroreductase was reported in Mtz-resistant H. pylori, an intact rdxA gene has also been reported in
Mtz-resistant H. pylori, suggesting that additional Mtz
resistance mechanisms exist in H. pylori. We explored the
nature of Mtz resistance among 544 clinical H. pylori
isolates to clarify the role of rdxA inactivation in Mtz resistance and to identify another gene(s) responsible for Mtz resistance in H. pylori. Mtz resistance was present in 33%
(181 of 544) of the clinical isolates. There was marked heterogeneity of resistance, with Mtz MICs ranging from 8 to
256 µg/ml.
rdxA inactivation resulted in Mtz MICs of up to 32 µg/ml
for 6 Mtz-sensitive H. pylori strains and 128 µg/ml for
one Mtz-sensitive strain. Single or dual (with rdxA)
inactivation of genes that encode ferredoxin-like protein (designated
fdxB) and NAD(P)H flavin oxidoreductase (frxA) also increased the MICs of Mtz for sensitive and resistant strains with
low to moderate levels of Mtz resistance. fdxB inactivation resulted in a lower level of resistance than that from rdxA
inactivation, whereas frxA inactivation resulted in MICs
similar to those seen with rdxA inactivation. Further
evidence for involvement of the frxA gene in Mtz resistance
included the finding of a naturally inactivated frxA but an
intact rdxA in an Mtz-resistant strain, complementation of
Mtz sensitivity from an Mtz-sensitive strain to an Mtz-resistant strain
or vice versa by use of naturally inactivated or functional
frxA genes, respectively, and transformation of an
Mtz-resistant Escherichia coli strain to an Mtz sensitive
strain by a naturally functional frxA gene but not an
inactivated frxA gene. These results are consistent with
the hypothesis that null mutations in fdxB,
frxA, or rdxA may be involved in Mtz resistance.
 |
INTRODUCTION |
Helicobacter pylori is
recognized as the major cause of peptic ulcer disease and a risk factor
for gastric adenocarcinoma and primary gastric lymphoma (4, 34,
35). H. pylori infection is one of the most common
infections worldwide and accounts for tremendous morbidity and
mortality. Clinical experience has demonstrated that H. pylori infection is not easy to cure. The primary impediments to
successful treatment are lack of compliance with the drug regimens and
development of antibiotic-resistant H. pylori
(15). Metronidazole (Mtz) was a critical ingredient of the
first successful therapy for H. pylori infection and remains
a major component of newer triple and quadruple therapies (16,
21). Monotherapy with Mtz results in the acquisition of Mtz
resistance by more than 50% of H. pylori isolates
(31), and Mtz-containing therapies are being undermined by
the development of resistance (36, 40).
Mtz has action against a wide variety of prokaryotic and eukaryotic
pathogens including H. pylori and is a mainstay of therapy for infections with organisms such as Bacteroides species,
Clostridium species, Trichomonas vaginalis,
Giardia lamblia, and Entamoeba histolytica
(8, 33). Understanding of the antimicrobial action and
resistance to Mtz has come from studies with anaerobic microorganisms such as Bacteroides, Trichomonas, and
Clostridium species (8, 9, 30). The cytotoxicity
of Mtz is not directly due to the final products of Mtz reduction but
to the unstable and/or less reduced intermediates that damage DNA,
resulting in strand breakage, helix destabilization, unwinding, and
cell death (5, 6). Reductive activation of Mtz depends on
the redox system of the target cell. Any redox system that possesses a
reduction potential more negative than that of Mtz will donate its
electrons preferentially to Mtz (27). The direct donors of
electrons in anaerobic bacteria are thought to be ferredoxin-like Fe-S
electron transport proteins such as ferredoxin (10, 29). In
anaerobic organisms, the redox potential is
430 to
460 mV, the
typical value for ferredoxin-like Fe-S proteins, whereas Mtz has a
reduction potential of
415 mV, making Mtz an efficient electron
acceptor. The lowest redox potentials obtainable by aerobic organisms
(e.g., Escherichia coli) are those of NAD or NADH (
320 mV)
and NADP or NADPH (
324 mV), such that these organisms are
intrinsically Mtz resistant as they are unable to reduce Mtz. However,
under aerobic conditions, one electron step can result in reoxidization
by oxygen to the original compound, producing inactive Mtz (8,
33). As noted above, the most important step in the antimicrobial
action of Mtz in bacteria is the reductive activation of the nitro
group of Mtz (which makes Mtz toxic), which is controlled by the redox
system of the target cell.
It has been proposed that the mode of action of Mtz in H. pylori is similar to that in anaerobic bacteria, although the
optimal in vitro culture conditions for this pathogen are
microaerophilic (2, 25). In addition, ferredoxin and
ferredoxin-like proteins have been identified from two complete
H. pylori genomic sequences (1, 39). Putative Mtz
nitroreductases include ferredoxin (HP0277; FdxA), flavodoxin (HP1161;
FldA), three ferredoxin-like proteins (HP1508 [which we named FdxB],
HP0588 [
subunit of 2-oxoglutarate oxidoreductase; OorDABC], and
HP1109 [
subunit of pyruvate ferredoxin oxidoreductase; PorCDAB]),
NAD(P)H flavin oxidoreductase (HP0642; FrxA), and oxygen-insensitive
NAD(P)H nitroreductase (HP0954; RdxA). OorDABC, PorCDAB, and FldA have
been purified from H. pylori, and the possible involvement
of those proteins in Mtz resistance has been described (20, 22,
23, 26). Furthermore, Mtz resistance in H. pylori has
also been suggested to be related to efficient DNA repair exerted by
the recA protein (3) and the decreasing
oxygen-scavenging capability at the site of Mtz reduction in resistant
H. pylori strains (38). The most convincing data
regarding Mtz resistance in H. pylori relate to inactivation of the rdxA gene, which inactivates Mtz nitroreductase
activity (14). However, other pathways that lead to Mtz
resistance exist because Mtz resistance has been described in H. pylori strains with an intact rdxA gene
(24). In addition, the inactivation of rdxA alone
is insufficient to explain the heterogeneity of Mtz resistance among
clinical H. pylori isolates (7, 42).
In this study, we present the rate of incidence and the heterogeneity
of Mtz resistance among 544 clinical H. pylori isolates from
the United States with the full range of Mtz resistance (Mtz MICs, 8 to
256 µg/ml). Putative H. pylori Mtz nitroreductases (e.g., FdxA, FdxB, FldA, FrxA, RdxA, OorD, and PorD) were inactivated to explore which gene or gene combinations are involved in Mtz resistance. We found that only the fdxB, frxA,
and rdxA genes could be inactivated without causing a lethal
effect on H. pylori. Mtz resistance was conferred by
inactivation of fdxB, frxA, or rdxA.
 |
MATERIALS AND METHODS |
Bacterial strains and culture conditions.
H. pylori
ATCC 700392 (which is the same as H. pylori 26695 [39]) was obtained from American Type Culture
Collection (Rockville, Md.), and all other H. pylori
isolates (n = 544) were obtained from the Veterans
Affairs Medical Center, Houston, Tex. The isolation of H. pylori strains from gastric biopsy specimens was performed as
described previously (17). The isolated H. pylori
strains including ATCC 700392 were routinely cultured on brain heart
infusion (BHI; Difco, Detroit, Mich.) agar plates containing 7% horse
blood in a microaerobic atmosphere (10% CO2 and 5%
O2) at 37°C for 2 to 3 days. Rifampin-resistant H. pylori 1857 for conjugation was generated by selection of
spontaneously resistant colonies on 7% horse serum-BHI agar plates
supplemented with 100 µg of rifampin per ml. When needed, selection
for chloramphenicol- or kanamycin-resistant H. pylori was
performed by adding 10 µg of chloramphenicol per ml or 15 µg of
kanamycin per ml to the 7% horse blood-BHI agar plate. E. coli cells (XL-Blue [Stratagene] or DH5
[Bethesda Research Laboratories, Inc.]) were cultured in Luria-Bertani (37)
broth or agar plates for the amplification of plasmids.
Determination of Mtz MICs.
The MICs for 544 H. pylori isolates were determined by twofold agar dilution. Agar
dilution plates were prepared with Mueller-Hinton (MH) agar as the base
medium. Aged sheep blood (2 weeks old) was added to the MH base medium
at a concentration of 5%. An Mtz solution (Sigma Chemical Co., St.
Louis, Mo.) was prepared in sterile distilled water and was added to
the 5% sheep blood-MH base medium to achieve serial twofold
concentrations of between 0.015 and 256 µg of Mtz per ml. Fresh
H. pylori isolates (2 to 3 days culture) were prepared in
saline to an optical density at 625 nm of between 0.38 and 0.4. With a
Steers-type replicating device (Cathra [no longer in business]), 1 to
5 µl of the adjusted inoculum was delivered to the agar plates. All
plates were incubated under CampyPak Plus conditions (Becton Dickinson
BBL, Cockeysville, Md.) for 3 days. The MIC was defined as the lowest
concentration of Mtz that completely inhibited the growth of the
inoculum. Mtz-resistant H. pylori ATCC 43504 was used as a
quality control organism. Any test in which the Mtz MIC for the quality
control organism was outside the approved range (64 to 256 µg/ml) was
completely discarded. The MICs for all H. pylori strains
with inactivated fdxB, frxA, and rdxA
genes were determined with 7% horse blood-BHI agar or 5% sheep
blood-MH agar plates supplemented with 0.5, 1, 2, 4, 8, 16, 32, 64, 128, or 256 µg of Mtz per ml and incubated for 3 to 4 days. The
measurement was repeated twice to confirm the results by using the same
7% horse blood-BHI medium supplemented with Mtz. The MIC for E. coli DH5
harboring frxA and/or rdxA genes
was determined by growing cells on LB agar plates supplemented with 10, 20, 40, 80, 160, or 320 µg of Mtz per ml.
PCR amplification of portions of fdxA,
fdxB, fldA, frxA, rdxA,
oorD, porD, and ureB (as a control)
from H. pylori and their in vitro inactivation
mutagenesis.
Portions of the genes that encode FdxA, FdxB, FldA,
FrxA, RdxA, OorD, PorD, and UreB were amplified by PCR with PCR primer pairs, as shown in Table 1. The identity
of each PCR-amplified fragment was confirmed by DNA sequencing, and the
confirmed DNA fragments were inserted into the EcoRV
restriction enzyme site of pBluescript SK(+) (Stratagene, La Jolla,
Calif.). The insert DNA was digested with an appropriate restriction
enzyme to inactivate the genes in vitro. A chloramphenicol resistance
gene cassette (cat) (41) was inserted into the
MunI and BalI sites of the insert DNAs for PorD
and OorD, respectively. The cat cassette was also inserted
into the BamHI, NsiI, and HindIII
sites of the insert DNAs for FdxA, FrxA, and FldA, respectively, and
into the Eco47III sites of the insert DNAs for FdxB and
RdxA. The resulting plasmids were named pGH67 for the plasmid with
fdxA::cat, pGH58 for that with
fdxB::cat, pGH64 for that with
fldA::cat, pGH130 for that with
frxA::cat, pGH55 for that with
rdxA::cat, pGH46 for that with
porD::cat, and pGH60 for that with
oorD::cat. A kanamycin resistance gene
cassette from pHel3 (km) (19) was also inserted
into the Eco47III site of insert DNA for RdxA, and the
resulting plasmid (pGH87) was used for dual inactivation by selection
on a plate with chloramphenicol and kanamycin. All the resulting
plasmids (1 to 2 µg) were used for inactivation of chromosomal genes
by natural transformation as described previously (19).
Cloning of frxA and rdxA genes from
H. pylori and DNA sequence analysis.
To isolate the
frxA and rdxA genes from H. pylori
ATCC 700392, 2600, 6013, 1857, and 1700, lambda phage genomic libraries were constructed with genomic DNAs from the strains as described previously (12). The frxA- and
rdxA-positive phage clones from each genomic library were
screened by plaque hybridization with the frxA- and
rdxA-specific PCR clones described above. The appropriate restriction fragments from the screened phage clones carrying the
frxA and rdxA genes were identified by
hybridization with the same probes and inserted into pBluescript SK(+)
or H. pylori-E. coli shuttle vector pHel2 (19).
The cloned frxA and rdxA genes from each H. pylori strain were used for DNA sequencing or complementation of
Mtz sensitivity. The DNA sequences of both DNA strands of the cloned
genes were determined at the Molecular Genetics Facility at the Baylor
College of Medicine. DNA sequence analysis was accomplished by the
BLAST network service of the National Center for Biotechnology Information.
Complementation of Mtz sensitivity.
For complementation of
an Mtz-sensitive strain to an Mtz-resistant strain, plasmid DNA [1 to
2 µg; the cloning vector was pBluescript SK(+), which is not
replicated in H. pylori] that carried naturally inactivated
frxA or rdxA genes was introduced into
Mtz-sensitive H. pylori 2600 by natural transformation
(19). Transformed H. pylori 2600 was screened on
a 7% horse blood-BHI agar plate supplemented with 4 µg of Mtz per
ml. For the complementation of an Mtz-resistant strain to an
Mtz-sensitive strain, the functional frxA and/or
rdxA gene from an Mtz-sensitive H. pylori 2600 isolate was cloned into H. pylori-E. coli shuttle vector
pHel2. The cloned frxA and/or rdxA gene in pHel2
was introduced into rifampin-resistant H. pylori strain 1857 (Mtz MIC, 128 µg/ml) by triparental conjugation (19), and
the conjugated H. pylori colonies (10 of each) were used to
measure Mtz sensitivity.
Mtz nitroreductase enzyme assay.
E. coli XL-1 Blue
carrying the cloned frxA and rdxA genes was
aerobically cultured to the late log phase in LB broth to measure Mtz
nitroreductase activity. The cells were harvested in phosphate-buffered saline containing 1 mM dithiothreitol (4°C) to protect
oxygen-sensitive enzymes and subjected to French pressure (600 lb;
Aminco, Urbana, Ill.). The cell-free crude extracts were centrifuged at
15,000 × g for 15 min at 4°C to remove the cell
debris, and the supernatant was immediately used as the enzyme source.
The Mtz nitroreductase activity from the cells was measured by the
method of Goodwin et al. (14). All enzyme reactions were
performed at 25°C in 1-ml volumes in triplicate, and enzymatic
activities were calculated as nanomoles per minute per milligram of
protein. The protein concentrations of the crude cell extracts were
determined by the Bradford procedure (Bio-Rad) with bovine serum
albumin as the standard.
Nucleotide sequence accession numbers.
The GenBank accession
numbers for the frxA genes are AF183174 for strain 2600, AF1833992 for strain 6013, AF183176 for strain 1857, and AF183175 for
strain 1700. The GenBank accession numbers for the rdxA
genes are AF184266 for strain 2600, AF184268 for strain 6013, AF184269
for strain 1857, and AF184267 for strain 1700.
 |
RESULTS |
Analysis of Mtz resistance among clinical H. pylori
isolates.
The heterogeneity of Mtz resistance in a single or
multiple colony expansion was demonstrated with 12 H. pylori
strains isolated from duodenal ulcer patients (7). To
understand the variations in the MICs for clinical H. pylori
isolates, we determined the MICs for 544 H. pylori strains
from the Veterans Affairs Medical Center, Houston, Tex., using the agar
dilution method as described above. Since strain ATCC 700392 was
considered Mtz sensitive (14), we carefully repeated the MIC
measurement using both the agar dilution method and the E-test as
described previously (18). The Mtz MIC for H. pylori ATCC 700392 was repeatedly 8 µg/ml by the agar dilution
method and 16 µg/ml by the E-test. The MICs for 544 clinical H. pylori isolates revealed that 33% were Mtz resistant (181 of 544 isolates; Mtz MICs,
8 µg/ml) and 67% were Mtz sensitive strains
(363 of 544 isolates; Mtz MICs,
4 µg/ml), with a wide spectrum in
the MICs (8 to
256 µg/ml) among Mtz-resistant strains (Fig.
1).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Heterogeneity of Mtz resistance among clinical H. pylori isolates. (A) Distribution of Mtz MICs for clinical
H. pylori isolates (n = 544). The MICs were
determined by twofold agar dilution methods. A total of 181 of 544 isolates were Mtz resistant. (B) Distribution of Mtz MICs for
Mtz-resistant H. pylori isolates (n = 181).
The MICs were used to analyze the Mtz-resistant H. pylori
isolates (181 of 544 isolates).
|
|
Inactivation analysis of genes encoding putative Mtz
nitroreductases (fdxA, fdxB, fldA,
frxA, rdxA, oorD, porD)
using genetic transformation of clinical H. pylori.
We
identified genes from the complete H. pylori genomic DNA
sequence (e.g., fdxA, fdxB, fldA,
frxA, rdxA, oorD, and porD) that encode putative Mtz nitroreductases. We evaluated the natural competence and transformation frequencies of 50 strains (25 Mtz-sensitive and 25 Mtz-resistant strains including H. pylori ATCC 700392) selected from among the 544 clinical H. pylori isolates. As a control gene for natural transformation, we
chose the ureB gene, which is not essential for H. pylori survival (11). The amino terminus (717 bp) of
the ureB gene from H. pylori ATCC 700392 was
amplified with a PCR primer pair (URE-A-URE-B; Table 1), and the
PCR-amplified ureB gene was inactivated by inserting a chloramphenicol resistance cassette (cat) (41).
The plasmid that contained the inactivated ureB gene (pUre1)
was used for inactivation of the H. pylori chromosomal
ureB gene. Of the 50 clinical H. pylori isolates,
18 strains (7 Mtz-sensitive and 11 Mtz-resistant strains) were able to
take up plasmid pUre1, as determined by expression of the
chloramphenicol resistance marker in the progeny H. pylori,
when it was applied by natural transformation (19). The
inactivation of ureB in the chromosomal DNA was confirmed by
PCR amplification of the ureB gene from parental and mutant H. pylori strains following Southern blot hybridization as
described previously (28) and by the urease-negative
activities of the ureB mutant H. pylori strains.
The transformation frequencies of the 18 H. pylori isolates
ranged from 4 × 10
3 (strain 2600) to 9 × 10
6 (strain 2399) viable cells with plasmid pUre1.
Thirty-two of the 50 H. pylori isolates were
nontransformable with pUre1. The 32 nontransformable strains were also
tested for natural competence by the method of Wang et al.
(41), and the antibiotic resistance markers from pUre1
failed to be introduced into these strains. We used the 18 transformable H. pylori strains for the inactivation of the
genes that encode putative Mtz nitroreductases. To test whether the
genes were inactivated without a lethal effect, in vitro inactivated
genes (by the cat gene) that encode putative Mtz
nitroreductases (pGH67 for fdxA, pGH58 for fdxB,
pGH64 for fldA, pGH130 for frxA, pGH55 for
rdxA, pGH60 for oorD, pGH46 for porD)
were introduced into H. pylori 2600. The results revealed that only fdxB, frxA, and rdxA were
inactivated without a lethal effect on H. pylori 2600. Inactivation of all the other genes (fdxA, fldA,
oorD, and porD) to produce viable cells failed
when the inactivation was repeated by the transformation method of either Heuermann and Haas (19) or Wang et al.
(41), suggesting that the cells were nonviable as a result
of the inactivation. The rdxA inactivation and the lethal
effect of oorDABC and porCDAB inactivation have
been reported previously (14, 22).
Mtz sensitivity analysis of H. pylori strains in which
fdxB, frxA, and rdxA are
inactivated.
Although the involvement of the null mutation in the
rdxA gene in Mtz resistance has been shown (14),
inactivation of rdxA results in a narrow range of MICs
(e.g., 16 to 32 µg/ml), which is different from the wide range of
MICs shown for clinical H. pylori isolates. To assess the
roles of the fdxB, frxA, and rdxA genes in Mtz resistance, we inactivated the fdxB,
frxA, and rdxA genes using the 18 transformable
H. pylori strains (7 Mtz-sensitive and 11 Mtz-resistant
strains). In addition, we also inactivated the fdxB or
frxA with the rdxA genes (dual inactivation).
Inactivation of one or both genes was confirmed by PCR amplification
following Southern blot hybridization as described previously
(28). To avoid chloramphenicol- or kanamycin-resistant
H. pylori mutants that contained a single crossover during
homologous recombination (i.e., false-positive recombination), new PCR
primer pairs positioned 193 to 960 bp away from the positions of the
sequences of the PCR primer pairs for the PCR clones used for
inactivation were designed (Table 2). The
integrities of the mutant genes were then reconfirmed by PCR
amplification with the new PCR primer pairs. The integrity of the
mutant phenotype (antibiotic resistance) was also confirmed with 10 colonies isolated from each mutant strain. All the confirmed mutant
strains were then analyzed for Mtz sensitivity (Table
3 and Table
4). The MICs for all mutant strains were
determined simultaneously, and the results were confirmed twice. The
MIC for a strain that had an inactivated fdxB gene and that
was constructed from the Mtz-sensitive strains was not different from
those for the parental strains. The MICs for strains that had
inactivated rdxA genes and that were constructed from seven
Mtz-sensitive strains were increased to 32 µg/ml for six strains, to
128 µg/ml for one strain (strain 2600). The MICs for the same seven
strains but with inactivated frxA genes were also increased
to the same levels as those for the strains with inactivated rdxA genes, irrespective of the slower growth rate of the
strains inactivated with the frxA genes. Interestingly, the
MICs for the seven Mtz-sensitive strains with the rdxA-fdxB
dual inactivation increased to 64 µg/ml (i.e., greater than that for
strains with either an inactivated rdxA gene or an
inactivated fdxB gene) for six strains and to 128 µg/ml
for one strain (strain 2600). These results are consistent with the
notion that fdxB inactivation is involved in Mtz resistance
but at a lower level than the level of involvement of rdxA
inactivation. In addition, the MICs for the seven Mtz-sensitive strains
with the frxA-rdxA dual inactivation increased to 128 µg/ml Mtz for six strains; the MIC for one strain (strain 2600)
increased to >256 µg/ml (Table 3).
We also analyzed the Mtz sensitivities of mutant strains constructed
from Mtz-resistant strains for which Mtz MICs were between 8 and 64 µg/ml. The MICs for the strains that had inactivated fdxB
genes and that were constructed from these resistant strains increased
up to eightfold, which provided additional evidence for the involvement
of fdxB inactivation in the Mtz resistance of H. pylori. The MICs for the strains that had inactivated
frxA or rdxA genes and that were constructed from
strains with low or moderate levels of resistance also increased up to
eightfold, suggesting that multiple genes or factors are involved in
the wide spectrum of Mtz resistance. Interestingly, the MIC for strain 6013 (32 µg/ml) was not changed when the frxA gene was
inactivated, whereas it increased fourfold when the rdxA
gene was inactivated, suggesting that strain 6013 contains a
nonfunctional frxA gene and a functional rdxA
gene. Additionally, the MICs for strains 9002 and 1857 (128 µg/ml)
and strains 1700 and 7200 (256 µg/ml) did not change because of
either frxA or rdxA inactivation, suggesting that
the strains may contain both nonfunctional frxA and
nonfunctional rdxA genes in their genomes (Table 4).
Cloning and nucleotide sequence analysis of frxA and
rdxA genes from H. pylori strains.
To
prove that naturally inactivated frxA genes are present in
clinical Mtz-resistant H. pylori isolates, the
frxA and rdxA genes were cloned from
Mtz-resistant strains and the nucleotide sequences were analyzed.
Because the DNA sequences of the PCR clones may not always be identical
to the parental DNA sequence, we constructed lambda phage libraries
using genomic DNAs purified from Mtz-resistant strains ATCC 700392, 6013, 1857, and 1700 and Mtz-sensitive strain 2600. frxA-
and rdxA-positive clones were isolated from each genomic
library, and the restriction enzyme maps of the initial clones are
shown in Fig. 2. The restriction enzyme
sites were highly diverse among the clones except in the frxA- and the rdxA-coding regions, reflecting the
genomic DNA sequence diversity in H. pylori strains. The DNA
sequences of the frxA and rdxA genes were
determined by using subclones of the initial clones, and the deduced
amino acid sequences of the genes were in alignment, as shown in Fig.
3. Nucleotide sequence analysis of an
~1.0-kb EcoRI fragment from pGH170 (cloned from strain
2600) revealed that the 971-bp fragment contained an frxA gene with 97% identity compared to the sequence of frxA
from strain J99 (Fig. 3B). Upstream of the frxA gene was the
carboxyl terminus (78 of 285 amino acids) of the putative 3-hydroxyacid
dehydrogenase gene, with only 2 bp of intervening nucleotides. The FrxA
proteins from resistant strains 6013 and 1857 were truncated by
insertion of one nucleotide (G) in the FrxA-coding region (between the
1st and 2nd amino acids), which shifted a reading frame of FrxA, and a
nonsense mutation (168th amino acid, CAA [Gln] to TAA [stop codon]), respectively (Fig. 3B). However, the FrxA protein from resistant strain 1700 was not truncated and showed 97% identity compared with the sequence of the FrxA protein from Mtz-sensitive strain J99 (Mtz MIC, 1 µg/ml) (1; Richard A. Alm,
personal communication). The FrxA protein from low-level Mtz-resistant strain ATCC 700392 showed 95% identity compared with the sequence of
the FrxA protein from strain J99. On the other hand, the RdxA proteins
from resistant strains 1857 and 1700 were truncated by nonsense
mutations. However, the RdxA protein from resistant strain 6013 was not
truncated and showed 98% identity compared with the sequence of the
RdxA protein from Mtz-sensitive strain J99. The RdxA protein from
low-level Mtz resistant strain ATCC 700392 showed 96% identity
compared with the sequence of the RdxA protein from strain J99 (Fig.
3A).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2.
Restriction endonuclease map of frxA and
rdxA clones from the lambda phage library constructed with
genomic DNAs from Mtz-sensitive and -resistant H. pylori
strains. The phage clones that carried an frxA gene or an
rdxA gene were screened by plaque hybridization. Restriction
fragments that contained an frxA or an rdxA gene
were identified by Southern hybridization. The restriction fragments
that contained the frxA or rdxA gene were
inserted into pBluescript SK(+) digested with the same or appropriate
restriction enzymes. pGH170 and pGH121 were cloned from the genomic DNA
of H. pylori 2600 (Mtz MIC, 2 µg/ml), pGH175 and pGH179
were cloned from the genomic DNA of H. pylori ATCC 700392 (Mtz MIC, 8 µg/ml), pGH174 and pGH101 were cloned from the genomic
DNA of H. pylori 6013 (Mtz MIC, 32 µg/ml), pGH178 and
pGH160 were cloned from the genomic DNA of H. pylori 1857 (Mtz MIC, 128 µg/ml), and pGH180 and pGH68 were cloned from the
genomic DNA of H. pylori 1700 (Mtz MIC, 256 µg/ml). E,
EcoRI; E47, Eco47III; H, HindIII;
N, NsiI; S, SphI; X, XbaI.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
Alignment of RdxA (A) and FrxA (B) amino acid sequences
from Mtz-sensitive and -resistant H. pylori strains.
Percentages in parentheses are percent identity.
|
|
Complementation analysis of Mtz sensitivity using cloned
frxA and rdxA genes in H. pylori.
It
has been shown that the Mtz resistance of H. pylori can be
transferred from a resistant strain to a sensitive strain by introduction of genomic DNA from a resistant strain into a sensitive strain (20, 41). On the basis of the results presented
above, the Mtz resistance acquired by the sensitive strain may be due to replacement of the inactivated rdxA and/or
frxA genes from the resistant strain. We examined whether
the naturally inactivated frxA genes from Mtz-resistant
strains were able to transfer Mtz resistance to Mtz-sensitive strains.
As shown in Table 5, plasmid DNA that
contained naturally inactivated frxA genes from
Mtz-resistant strains 6013 and 1857 (pGH174 and pGH160, respectively)
successfully transferred Mtz resistance to Mtz-sensitive strain 2600 with transformation frequencies of 0.5 × 103 and
0.58 × 103 CFU per 1 µg of plasmid DNA,
respectively. In the same complementation study, the naturally
inactivated rdxA genes from Mtz-resistant strains 1857 and
1700 (pGH178 and pGH68, respectively) also transferred Mtz resistance
to Mtz-sensitive strain 2600 with transformation frequencies of
0.52 × 103 and 0.5 × 104 CFU per 1 µg of plasmid DNA, respectively. However, none of the plasmid DNAs
that contained functional frxA or rdxA genes
(pGH170, pGH121, pGH101, and pGH180) transferred Mtz resistance to
Mtz-sensitive strain 2600. We also introduced a functional
frxA and/or rdxA gene cloned in the H. pylori-E. coli shuttle vector (pHel2) into one of the
Mtz-resistant strains to confirm whether the functional genes were able
to restore the Mtz sensitivities of the strains. Mtz resistance in
strain 1857 (Mtz MIC, 128 µg/ml) was partially decreased by a
functional frxA gene (pGH177) or a functional
rdxA gene (pGH127), but it was made completely susceptible
(MIC, 1 µg/ml) when both functional frxA and
rdxA genes (pGH181) were introduced. These results are
consistent with the notion that the frxA inactivation is
involved in Mtz resistance.
Expression of cloned frxA and rdxA genes in
E. coli.
We performed the Mtz nitroreductase assay using
E. coli strains that harbored cloned frxA genes
or an rdxA gene (as a positive control) to verify whether
the cloned frxA gene from the Mtz-sensitive H. pylori strain possessed Mtz nitroreductase activity. Mtz
nitroreductase activity was always demonstrable in the E. coli strains that harbored a cloned rdxA gene from the
Mtz-sensitive strain H. pylori 2600, with the enzyme
activity varying between 5.3 and 7.8 nmol/mg/min. By the same assay Mtz
nitroreductase activity was not detected in the E. coli
strains that harbored a cloned frxA gene from Mtz-sensitive strain H. pylori 2600. The difficulty in measuring Mtz
nitroreductase activity in crude extracts may be due to oxidation of
key components during the preparation of crude extracts or the
interference of endogenous nitroreductase from E. coli as
described by Goodwin et al. (14).
An alternative method for detection of Mtz nitroreductase activity in
E. coli is an in vivo assay, which measures the MICs for
E. coli strains that harbor a cloned frxA or
rdxA gene from H. pylori. The in vivo assay is
based on expression of a cloned frxA or rdxA gene
in E. coli cells and measurement of the Mtz sensitivities of
the E. coli cells that harbor the cloned genes. If the
cloned gene expresses and produces Mtz nitroreductase in intrinsically
Mtz-resistant E. coli, the enzyme should convert nontoxic
Mtz to toxic Mtz and the E. coli cells will become sensitive to Mtz (decreased MICs). Since E. coli DH5
is
intrinsically Mtz resistant (MIC, >320 µg/ml), we introduced the
cloned frxA and rdxA genes from Mtz-sensitive and
-resistant H. pylori strains. The E. coli DH5
cells that harbored the genes were cultured aerobically in LB broth and
spotted (5 µl of each strain) onto LB agar plates supplemented with
10 to 320 µg of Mtz per ml. The plates were then incubated
aerobically at 37°C for 18 h. The E. coli DH5
cells that harbored either the frxA or the rdxA
gene cloned from Mtz-sensitive strain H. pylori 2600 (pGH170
or pGH121, respectively) did not grow in the presence of 20 to 40 µg
of Mtz per ml. In contrast, only the vector [pBluescript SK(+) or
pHel2] or plasmid that contained a part of the frxA or the
rdxA gene (pGH172, XbaI-NsiI fragment
of pGH170; pGH104, Eco47III-HindIII
fragment of pGH121; see Fig. 2) grew on medium with 320 µg of Mtz per
ml. Interestingly, E. coli cells that harbored the
SphI-XbaI fragment (2.5 kb; pGH173) of pGH170
also grew on medium with 320 µg of Mtz per ml (Table 6). E. coli cells that
harbored the same frxA or rdxA gene in the
H. pylori-E. coli shuttle vector (pHel2) were also sensitive to Mtz, but the MICs for the strains were slightly higher (MICs, 40 to
80 µg/ml for strains with pGH127 and pGH177) than those obtained when
pBluescript SK(+) was used as a cloning vector. In addition, E. coli cells that harbored both genes (frxA and rdxA) in pHel2 (pGH181) did not grow on LB agar plates
supplemented with 20 to 40 µg of Mtz per ml. Although the MICs were
slightly variable in the in vivo assay, the results were reproducible
and consistent. Therefore, we applied the assay to the other cloned frxA and rdxA genes from Mtz-resistant H. pylori strains. E. coli cells that harbored a
frxA gene (pGH175) or a rdxA gene (pGH179) from
H. pylori ATCC 700392 did not grow on LB agar plates
supplemented with 80 to 160 and 20 to 40 µg of Mtz per ml,
respectively. Repetition of these assays with pGH175 and pGH179 gave
identical results. We also confirmed the involvement of an
frxA gene from strain ATCC 700392 in Mtz sensitivity by
comparing the expression of a part of the frxA gene
(XbaI-NsiI fragments of pGH175; Fig. 2) that,
when expressed in E. coli, resulted in loss of Mtz
nitroreductase activity of the gene. E. coli cells that
harbored frxA (pGH174 and pGH160) or rdxA (pGH178
and pGH68) from Mtz-resistant strains 6013, 1857, and 1700 grew on LB
agar plates supplemented with 320 µg of Mtz per ml, while E. coli cells that harbored frxA (pGH180) and
rdxA (pGH101) from Mtz-resistant strains 6013 and 1700 did not grow on LB agar plates supplemented with 20 to 40 µg of Mtz per
ml (Table 6).
 |
DISCUSSION |
H. pylori infection is responsible for most cases of
peptic ulcer disease, and successful treatment of the infection results in cure of the disease. In the last decade, a number of regimens for
the treatment of H. pylori infection have been introduced. Mtz resistance among H. pylori isolates has been found
worldwide and has become an increasing problem for current therapies.
The deciphering of the Mtz resistance mechanism may provide critical information for (i) the appropriate antibiotic treatment of this infection, (ii) better therapy for infections caused by Mtz-resistant H. pylori strains and perhaps for those caused by other
Mtz-resistant microorganisms, and (iii) the design of new antibiotics.
The mechanism of Mtz resistance in H. pylori was initially
explained by mutations in an rdxA gene (14).
However, as shown here and by Jenks et al. (24), an intact
rdxA gene can be found in some Mtz-resistant strains,
suggesting that an additional resistance mechanism(s) is involved in
Mtz resistance. To investigate whether additional Mtz resistance
mechanisms were present in H. pylori, we examined the nature
of Mtz resistance among 544 clinical H. pylori isolates, clarified the role of an rdxA gene in a wide range of
Mtz-resistant H. pylori isolates, and explored additional
genes that might be involved in Mtz resistance. The 33% rate of Mtz
resistance found in this study is in agreement with the rates detected
by other investigators (13, 32). The proposed breakpoint for
Mtz resistance used in this study was an MIC of
8 µg/ml, which is
based on the finding that inactivation of the rdxA or
frxA genes of H. pylori strains for which the
MICs are
4 µg/ml always increased the MICs to 32 µg/ml but
inactivation of strains for which the MICs are
8 µg/ml increased
the MICs to >32 µg/ml. Inactivation of fdxB in strains
for which the MICs are
8 µg/ml also increased the MICs compared
with those for the parental strains. These results suggest that
acquired Mtz resistance begins at an MIC of approximately
8 µg/ml.
Mtz MICs for Mtz-sensitive strain 2600 fluctuated from <1 to 4 µg/ml, but the strain never grew in the presence of 4 µg of Mtz per
ml (MIC, <8 µg/ml).
Inactivation of rdxA in Mtz-sensitive strains always
increased the MIC to 32 µg/ml. For the Mtz-sensitive strains with
inactivated rdxA genes, the MICs were never lower than 32 µg/ml for any of the isolates, suggesting that complete
rdxA inactivation may generally increase the MIC to 32 µg/ml (moderate level of Mtz resistance). For one strain (strain
2600), inactivation of rdxA increased the Mtz MIC to 128 µg/ml (high-level resistance), suggesting that rdxA
inactivation may play a role in high-level Mtz resistance, although the
possibility that an additional factor(s) or a lack of a factor(s) may
also be involved in high-level Mtz resistance. This observation was
also shown in high-level Mtz-resistant clinical isolate 1700, in which
only rdxA was inactivated.
Theoretically, any protein that produces or inhibits Mtz nitroreductase
activity could be involved in Mtz sensitivity. Purified PorCDAB and
FldA proteins were tested in vitro and the results suggested that these
proteins are putative Mtz nitroreductases (23, 26).
Inactivation of PorCDAB was lethal to H. pylori (22), and we also confirmed that inactivation of the
porCDAB or fldA gene was lethal to H. pylori. The inactivation of other ferredoxin-like or -linked
proteins (FdxA and OorD) that may have Mtz nitroreductase activities
was also lethal to H. pylori. Since FdxA, FldA, PorCDAB, and
OorDABC appeared to be essential for cell survival, it was difficult to
assess the roles of these proteins in Mtz resistance. Although
inactivation of a single gene (fdxB) in an Mtz-sensitive
strain had no effect on the MIC compared to that for the parental
strain, the rdxA-fdxB dual inactivation increased the MIC
twofold compared with that for Mtz-sensitive strain in which a single
gene (rdxA) was inactivated (from 32 to 64 µg/ml). In
addition, the MICs for the low-level Mtz-resistant strains (MICs, 8 µg/ml) in which a single gene (fdxB) was inactivated were
also increased fourfold and eightfold, as shown in Table 4. These
results indicate that the fdxB inactivation is also involved
in increasing the level of Mtz resistance. It is not clear why the MIC
was unchanged for an Mtz-sensitive strain with an inactivated
fdxB gene. However, it could be possible that the Mtz
nitroreductase activities from RdxA and FrxA were much higher than that
from FdxB in the Mtz-sensitive strain that contained fully functional
rdxA and frxA genes, which might lead to no
effect of the single fdxB inactivation.
Expression of the frxA gene cloned from H. pylori
26695 in E. coli resulted in no significant difference in
the Mtz sensitivity of Mtz-resistant E. coli
(14). However, Mtz sensitivity analysis by frxA
inactivation of Mtz-sensitive H. pylori strains and H. pylori strains with low-level or moderate Mtz resistance showed that frxA inactivation conferred Mtz resistance at a level
similar to that achieved by rdxA inactivation. In
particular, nucleotide sequence analysis of the frxA genes
from clinical isolates with moderate and high levels of Mtz resistance
provided genetic evidence of the involvement of frxA in Mtz
resistance. One moderately Mtz-resistant strain 6013 (Mtz MIC, 32 µg/ml) carried an inactivated frxA gene but a fully
functional rdxA gene. Mtz sensitivity analysis of strains
with inactivated frxA and/or rdxA genes showed
that strain 1857 with both inactivated frxA and inactivated
rdxA genes had a high level of Mtz resistance, as shown for
strain 2600, in which both frxA and rdxA were
inactivated. In addition, Mtz sensitivity analysis of strains with
inactivated frxA and/or rdxA genes allowed us to
find strain 1700, which contained a single inactivated gene (rdxA) and which had a high level of Mtz resistance, as was
also shown for strain 2600, which had a single inactivated gene
(rdxA). Comparative analyses of complementation of Mtz
sensitivity from either an Mtz-sensitive strain to an Mtz-resistant
strain, or vice versa, with inactivated or functional frxA
and rdxA genes, respectively, coupled with the expression of
cloned inactivated and functional frxA and rdxA
genes in E. coli, prove that the frxA gene is
involved in Mtz resistance. Comparison of FrxA and RdxA protein
sequences from H. pylori ATCC 700392 showed 25% identity and 63% similarity with the absolutely conserved amino acid PW (Pro,
Trp) at positions 51 and 52 of classical nitroreductases (14), indicating that the FrxA protein also possesses Mtz
nitroreductase activity, as shown for the RdxA protein.
We also confirmed that the frxA gene from H. pylori strain ATCC 700392 was involved in Mtz resistance. The
frxA gene cloned from strain ATCC 700392 [5.3-kb
XbaI fragment in pBluescript SK(+)] was expressed in
E. coli and converted the Mtz MICs for the cells from >320
µg/ml to 80 to 160 µg/ml. Although the difference in the MIC was
not very impressive, as shown for the frxA gene from strain
2600 (Mtz MIC, >320 to 20- to 40 µg/ml), cloning of the frxA gene from strain ATCC 700392 significantly decreased
the MIC. However, the MIC for strain ATCC 700392 with an inactivated frxA gene did not increase as much as those for strains 2617 and 2593 with inactivated frxA genes (for which the MICs
were the same as that for strain ATCC 700392 [MIC, 8 µg/ml]),
suggesting that frxA from strain ATCC 700392 may be
partially inactivated. Indeed, 8 amino acids in the N terminus (the
first 80 amino acids) of FrxA from strain ATCC 700392 were replaced by
other amino acids, while none of the amino acids in the same FrxA from
Mtz-sensitive strain 2600 was replaced when the sequence was compared
with the FrxA sequence of Mtz-sensitive strain J99. The MIC of 8 µg/ml for strain ATCC 700392 was additional supporting evidence for the partial inactivation of the frxA gene. Another feature
of frxA was the fact that a 972-bp EcoRI fragment
and an ~2.5-kb SphI-XbaI fragment from pGH170
(which carried the frxA gene from strain 2600) did not
change MICs in E. coli (no difference in Mtz sensitivity).
These results indicate that at least a 2.0-kb upstream flanking region
of the frxA gene is required for appropriate Mtz
nitroreductase expression in E. coli. Nucleotide sequence analysis showed that the FrxA protein followed a putative 3-hydroxyacid dehydrogenase at the carboxyl terminus with only two intervening nucleotide sequences, suggesting that the frxA mRNA may be
cotranscribed with an upstream gene(s).
In summary, the overall finding of this study is that two genes
(fdxB and frxA), in addition to the
rdxA gene, are responsible for the Mtz resistance of
H. pylori. The inactivation of fdxB, frxA, or rdxA is involved in different levels of
Mtz resistance in H. pylori. These results lead us to
hypothesize that the wide range of Mtz MICs seen for clinical H. pylori isolates may be due to partial and/or complete inactivation
of the fdxB, frxA, and rdxA genes.
Indeed, Mtz MICs of 32, 64, 128, and 256 µg/ml were created by
inactivation of one or two of the three genes in Mtz-sensitive strains.
Additionally, Mtz MICs of 8 and 16 µg/ml are also theoretically
achievable by partial inactivation of the genes, as shown for strain
ATCC 700392. However, the high-level Mtz resistance of some strains
(e.g., strains 2600 and 1700) in which a single frxA or
rdxA gene is inactivated suggests that additional Mtz
resistance mechanisms exist in H. pylori.
 |
ACKNOWLEDGMENTS |
Thanks to Richard A. Alm for information on the Mtz MIC for
H. pylori strain J99, to R. Haas for providing H. pylori-E. coli shuttle vectors and E. coli strain GC7
(pRK2013), and to D. E. Taylor for providing the chloramphenicol
resistance gene cassette.
This work was supported in part by the U.S. Department of Veterans Affairs.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Rm 3A-320
(111D), Veterans Affairs Medical Center, 2002 Holcombe Blvd., Houston,
TX 77030. Phone: (713) 794-7276. Fax: (713) 795-4471. E-mail:
dkwon{at}bcm.tmc.edu.
 |
REFERENCES |
| 1.
|
Alm, R. A.,
L. L. Ling,
D. T. Moir,
B. L. King,
E. D. Brown,
P. C. Doig,
D. R. Smith,
B. Noonan,
B. C. Guild,
B. L. deJonge,
G. Carmel,
P. J. Tummino,
A. Caruso,
M. Uria-Nickelsen,
D. M. Mills,
C. Ives,
R. Gibson,
D. Merberg,
S. D. Mills,
Q. Jinag,
D. E. Taylor,
G. F. Vovis, and T. J. Trust.
1999.
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.
Nature
397:176-180[CrossRef][Medline].
|
| 2.
|
Cederbrant, G.,
G. Kahlmeter, and A. Ljungh.
1992.
Proposed mechanism for metronidazole resistance in Helicobacter pylori.
J. Antimicrob. Chemother.
29:115-120[Abstract/Free Full Text].
|
| 3.
|
Chang, K. C.,
S. W. Ho,
J. C. Yang, and J. T. Wang.
1997.
Isolation of a genetic locus associated with metronidazole resistance in Helicobacter pylori.
Biochem. Biophys. Res. Commun.
236:785-788[CrossRef][Medline].
|
| 4.
|
Crump, M.,
M. Gospodarowicz, and F. A. Shepherd.
1999.
Lymphoma of the gastrointestinal tract.
Semin. Oncol.
26:324-337[Medline].
|
| 5.
|
Declerk, P. J., and C. J. Ranter.
1986.
In vitro reductive activation of nitroimidazoles.
Biochem. Pharmacol.
35:59-61[CrossRef][Medline].
|
| 6.
|
Declerk, P. J.,
C. J. de Ranter, and G. Volckaert.
1983.
Base specific interaction of reductively activated nitroimidazoles with DNA.
FEBS Lett.
164:145-148[CrossRef][Medline].
|
| 7.
|
Dore, M. P.,
M. S. Osato,
D. H. Kwon,
D. Y. Graham, and F. A. K. El-Zaatari.
1998.
Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates.
Clin. Infect. Dis.
27:84-89[Medline].
|
| 8.
|
Edwards, D. I.
1993.
Nitroimidazole drugs action and resistance mechanisms. I. Mechanisms of action.
J. Antimicrob. Chemother.
31:9-20[Free Full Text].
|
| 9.
|
Edwards, D. I.
1993.
Nitroimidazole drugs action and resistance mechanisms. II. Mechanisms of resistance.
J. Antimicrob. Chemother.
31:201-210[Free Full Text].
|
| 10.
|
Edwards, D. I.,
M. Dye, and H. Carne.
1973.
The selective toxicity of antimicrobial nitroheterocyclic drugs.
J. Gen. Microbiol.
76:135-145[Medline].
|
| 11.
|
Ferrero, R. L.,
V. Cussac,
P. Courcoux, and A. Labigne.
1992.
Construction of isogenic urease-negative mutants of Helicobacter pylori by allelic exchange.
J. Bacteriol.
174:4212-4217[Abstract/Free Full Text].
|
| 12.
|
Ge, Z.,
K. Hiratsuka, and D. E. Taylor.
1995.
Nucleotide sequence and mutational analysis indicate that two Helicobacter pylori genes encode a P-type ATPase and a cation-binding protein associated with copper transport.
Mol. Microbiol.
15:97-106[CrossRef][Medline].
|
| 13.
|
Glupczynski, Y.
1998.
Antimicrobial resistance in Helicobacter pylori: a global overview.
Acta Gastro-Enterol. Belg.
61:357-366[Medline].
|
| 14.
|
Goodwin, A.,
D. Kersulyte,
G. Sisson,
S. J. O. Veldhuyzen van Zanten,
D. E. Berg, and P. S. Hoffman.
1998.
Metronidazole-resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NAD(P)H nitroreductase.
Mol. Microbiol.
28:383-393[CrossRef][Medline].
|
| 15.
|
Graham, D. Y.,
W. A. de Boer, and G. N. Tytgat.
1996.
Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance.
Am. J. Gastroenterol.
91:1072-1076[Medline].
|
| 16.
|
Graham, D. Y.
1998.
Antibiotic resistance in Helicobacter pylori: implications for therapy.
Gastroenterology
115:1272-1277[CrossRef][Medline].
|
| 17.
|
Hachem, C. Y.,
J. E. Clarridge,
D. G. Evans, and D. Y. Graham.
1995.
Comparison of agar based media for primary isolation of Helicobacter pylori.
J. Clin. Pathol.
48:714-716[Abstract/Free Full Text].
|
| 18.
|
Hachem, C. Y.,
J. E. Clarridge,
R. Reddy, and D. Y. Graham.
1996.
Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole.
Diagn. Microbiol. Infect. Dis.
24:37-41[CrossRef][Medline].
|
| 19.
|
Heuermann, D., and R. Haas.
1998.
A stable shuttle vector system for efficient genetic complementation of Helicobacter pylori strains by transformation and conjugation.
Mol. Gen. Genet.
257:519-528[CrossRef][Medline].
|
| 20.
|
Hoffman, P. S.,
A. Goodwin,
J. Johnsen,
K. Magee, and S. J. Veldhuygen van Zanten.
1996.
Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance.
J. Bacteriol.
178:4822-4829[Abstract/Free Full Text].
|
| 21.
|
Houben, M. H.,
D. V. Beek,
E. F. Hensen,
A. J. Craen,
E. A. Rauws, and G. N. Tytgat.
1999.
A systematic review of Helicobacter pylori eradication therapy the impact of antimicrobial resistance on eradication rates.
Aliment. Pharmacol. Ther.
13:1047-1055[CrossRef][Medline].
|
| 22.
|
Hughes, N. J.,
C. L. Clayton,
P. A. Chalk, and D. J. Kelly.
1998.
Helicobacter pylori porCDAB and oorDABC genes encode distinct pyruvate:flavodoxin and 2-oxoglutarate:acceptor oxidoreductases which mediate electron transport to NADP.
J. Bacteriol.
180:1119-1128[Abstract/Free Full Text].
|
| 23.
|
Hughes, N. J.,
P. A. Chalk,
C. L. Clayton, and D. J. Kelly.
1995.
Identification of carboxylation enzymes and characterization of a novel four-subunit pyruvate:flavodoxin oxidoreductase from Helicobacter pylori.
J. Bacteriol.
177:3953-3959[Abstract/Free Full Text].
|
| 24.
|
Jenks, P. J.,
R. L. Ferrero, and A. Labigne.
1999.
The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori.
J. Antimicrob. Chemother.
43:753-758[Abstract/Free Full Text].
|
| 25.
|
Jorgensen, M. A.,
J. Manos,
G. L. Mendz, and S. L. Hazell.
1998.
The mode of action of metronidazole in Helicobacter pylori: futile cycling or reduction?
J. Antimicrob. Chemother.
41:67-75[Abstract/Free Full Text].
|
| 26.
|
Kaihovaara, P.,
J. Hook-Nikanne,
M. Uusi-Oukari,
T. U. Kosunen, and M. Salaspuro.
1998.
Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori.
J. Antimicrob. Chemother.
41:171-177[Abstract/Free Full Text].
|
| 27.
|
Kedderis, G. L.,
L. S. Argenbright, and G. T. Miwa.
1988.
Mechanism of reductive activation of a 5-nitroimidazole by flavoproteins: model studies with dithionite.
Arch. Biochem. Biophys.
262:40-48[CrossRef][Medline].
|
| 28.
|
Kwon, D. H.,
J. S. Woo,
C. L. Perng,
M. F. Go,
D. Y. Graham, and F. A. K. El-Zaatari.
1998.
The effect of galE gene inactivation on lipopolysaccharide profile of Helicobacter pylori.
Curr. Microbiol.
37:144-148[CrossRef][Medline].
|
| 29.
|
Lindmark, D. G., and M. Muller.
1976.
Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles.
Antimicrob. Agents Chemother.
10:476-482[Abstract/Free Full Text].
|
| 30.
|
Lockerby, L.,
H. R. Rabin, and E. J. Laishley.
1985.
Role of the phosphoroclastic reaction of Clostridium pasteurianum in the reduction of metronidazole.
Antimicrob. Agents Chemother.
27:863-867[Abstract/Free Full Text].
|
| 31.
|
Megraud, F.
1994.
Helicobacter pylori resistance to antibiotics, p. 570-583.
In
R. H. Hunt, and G. N. J. Tytgat (ed.), Helicobacter pylori: basic mechanisms to clinical cure. Kluwer Academic Publishers, Dordrecht, The Netherlands.
|
| 32.
|
Megraud, F.
1998.
Antibiotic resistance in Helicobacter pylori infection.
Br. Med. Bull.
54:207-216[Abstract/Free Full Text].
|
| 33.
|
Muller, M.
1983.
Mode of action of metronidazole on anaerobic bacteria and protozoa.
Surgery
93:165-171[Medline].
|
| 34.
|
Parsonnet, J.
1998.
Helicobacter pylori.
Infect. Dis. Clin. N. Am.
12:185-197[CrossRef][Medline].
|
| 35.
|
Parsonnet, J.
1998.
Helicobacter pylori: the size of the problem.
Gut
43(Suppl. 1):S6-S9[Free Full Text].
|
| 36.
|
Realdi, G.,
M. P. Dore,
A. Piana,
A. Atzei,
M. Carta,
L. Cugia,
A. Manca,
B. M. Are,
G. Massarelli,
I. Mura,
A. Maida, and D. Y. Graham.
1999.
Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies.
Helicobacter
4:106-112[CrossRef][Medline].
|
| 37.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 38.
|
Smith, M. A., and D. I. Edwards.
1997.
Oxygen scavenging, NADH oxidase and metronidazole resistance in Helicobacter pylori.
J. Antimicrob. Chemother.
39:347-353[Abstract/Free Full Text].
|
| 39.
|
Tomb, J. F.,
O. White,
A. R. Kerlavage,
R. A. Clayton,
G. G. Sutton,
R. D. Fleischmann,
K. A. Ketchum,
H. P. Klenk,
S. Gill,
B. A. Dougherty,
K. Nelson,
J. Quackenbush,
L. Zhou,
E. F. Kirkness,
S. Peterson,
B. Loftus,
D. Richardson,
R. Dodson,
H. G. Khalak,
A. Glodek,
K. McKenny,
L. M. Fitzegerald,
N. M. Lee,
M. D. Adams,
E. K. Hickey,
D. E. Berg,
J. D. Gocayne,
T. R. Utterback,
J. D. Peterson,
J. M. Kelley,
M. D. Cotton,
J. M. Weidman,
C. Fujii,
C. Bowman,
L. Watthey,
E. Wallin,
W. S. Hays,
M. Borodovsky,
P. D. Karp,
H. O. Smith,
C. M. Fraser, and J. C. Venter.
1997.
The complete genome sequence of the gastric pathogen Helicobacter pylori.
Nature
388:539-547[CrossRef][Medline].
|
| 40.
|
Van der Wouden, E. J.,
J. C. Thijs,
A. A. van Zwet,
W. J. Sluiter, and J. H. Kleibeuker.
1999.
The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis.
Am. J. Gastroenterol.
94:1751-1759[Medline].
|
| 41.
|
Wang, Y.,
K. P. Roos, and D. E. Taylor.
1993.
Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker.
J. Gen. Microbiol.
139:2485-2493[Medline].
|
| 42.
|
Weel, J. F.,
R. W. van der Hulst,
Y. Gerrits,
G. N. Tytgat,
A. van der Ende, and J. Dankert.
1996.
Heterogeneity in susceptibility to metronidazole among Helicobacter pylori isolates from patients with gastritis or peptic ulcer disease.
J. Clin. Microbiol.
34:2158-2162[Abstract].
|
Antimicrobial Agents and Chemotherapy, August 2000, p. 2133-2142, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wu, J. Y., Kim, J. J., Reddy, R., Wang, W. M., Graham, D. Y., Kwon, D. H.
(2005). Tetracycline-Resistant Clinical Helicobacter pylori Isolates with and without Mutations in 16S rRNA-Encoding Genes. Antimicrob. Agents Chemother.
49: 578-583
[Abstract]
[Full Text]
-
Leiros, H.-K. S., Kozielski-Stuhrmann, S., Kapp, U., Terradot, L., Leonard, G. A., McSweeney, S. M.
(2004). Structural Basis of 5-Nitroimidazole Antibiotic Resistance: THE CRYSTAL STRUCTURE OF NimA FROM DEINOCOCCUS RADIODURANS. J. Biol. Chem.
279: 55840-55849
[Abstract]
[Full Text]
-
Gerrits, M. M, van der Wouden, E.-J., Bax, D. A, van Zwet, A. A, van Vliet, A. H., de Jong, A., Kusters, J. G, Thijs, J. C, Kuipers, E. J
(2004). Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori. J Med Microbiol
53: 1123-1128
[Abstract]
[Full Text]
-
Nahar, S., Mukhopadhyay, A. K., Khan, R., Ahmad, M. M., Datta, S., Chattopadhyay, S., Dhar, S. C., Sarker, S. A., Engstrand, L., Berg, D. E., Nair, G. B., Rahman, M.
(2004). Antimicrobial Susceptibility of Helicobacter pylori Strains Isolated in Bangladesh. J. Clin. Microbiol.
42: 4856-4858
[Abstract]
[Full Text]
-
Diniz, C. G., Farias, L. M., Carvalho, M. A. R., Rocha, E. R., Smith, C. J.
(2004). Differential gene expression in a Bacteroides fragilis metronidazole-resistant mutant. J Antimicrob Chemother
54: 100-108
[Abstract]
[Full Text]
-
Chisholm, S. A., Owen, R. J.
(2004). Frameshift mutations in frxA occur frequently and do not provide a reliable marker for metronidazole resistance in UK isolates of Helicobacter pylori. J Med Microbiol
53: 135-140
[Abstract]
[Full Text]
-
Kwon, D. H., Dore, M. P., Kim, J. J., Kato, M., Lee, M., Wu, J. Y., Graham, D. Y.
(2003). High-Level {beta}-Lactam Resistance Associated with Acquired Multidrug Resistance in Helicobacter pylori. Antimicrob. Agents Chemother.
47: 2169-2178
[Abstract]
[Full Text]
-
Mukhopadhyay, A. K., Jeong, J.-Y., Dailidiene, D., Hoffman, P. S., Berg, D. E.
(2003). The fdxA Ferredoxin Gene Can Down-Regulate frxA Nitroreductase Gene Expression and Is Essential in Many Strains of Helicobacter pylori. J. Bacteriol.
185: 2927-2935
[Abstract]
[Full Text]
-
Chisholm, S. A., Owen, R. J.
(2003). Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance. J Antimicrob Chemother
51: 995-999
[Abstract]
[Full Text]
-
Latham, S. R., Labigne, A., Jenks, P. J.
(2002). Production of the RdxA protein in metronidazole-susceptible and -resistant isolates of Helicobacter pylori cultured from treated mice. J Antimicrob Chemother
49: 675-678
[Abstract]
[Full Text]
-
Owen, R J
(2002). Molecular testing for antibiotic resistance in Helicobacter pylori. Gut
50: 285-289
[Abstract]
[Full Text]
-
Kwon, D. H., Hulten, K., Kato, M., Kim, J. J., Lee, M., El-Zaatari, F. A. K., Osato, M. S., Graham, D. Y.
(2001). DNA Sequence Analysis of rdxA and frxA from 12 Pairs of Metronidazole-Sensitive and -Resistant Clinical Helicobacter pylori Isolates. Antimicrob. Agents Chemother.
45: 2609-2615
[Abstract]
[Full Text]
-
Latham, S. R., Owen, R. J., Elviss, N. C., Labigne, A., Jenks, P. J.
(2001). Differentiation of Metronidazole-Sensitive and -Resistant Clinical Isolates of Helicobacter pylori by Immunoblotting with Antisera to the RdxA Protein. J. Clin. Microbiol.
39: 3052-3055
[Abstract]
[Full Text]
-
Jeong, J.-Y., Mukhopadhyay, A. K., Akada, J. K., Dailidiene, D., Hoffman, P. S., Berg, D. E.
(2001). Roles of FrxA and RdxA Nitroreductases of Helicobacter pylori in Susceptibility and Resistance to Metronidazole. J. Bacteriol.
183: 5155-5162
[Abstract]
[Full Text]
-
Kim, J. J., Reddy, R., Lee, M., Kim, J. G., El-Zaatari, F. A. K., Osato, M. S., Graham, D. Y., Kwon, D. H.
(2001). Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother
47: 459-461
[Abstract]
[Full Text]
-
Wang, G., Wilson, T. J. M., Jiang, Q., Taylor, D. E.
(2001). Spontaneous Mutations That Confer Antibiotic Resistance in Helicobacter pylori. Antimicrob. Agents Chemother.
45: 727-733
[Abstract]
[Full Text]
-
Kwon, D. H., Lee, M., Kim, J. J., Kim, J. G., El-Zaatari, F. A. K., Osato, M. S., Graham, D. Y.
(2001). Furazolidone- and Nitrofurantoin-Resistant Helicobacter pylori: Prevalence and Role of Genes Involved in Metronidazole Resistance. Antimicrob. Agents Chemother.
45: 306-308
[Abstract]
[Full Text]
-
Jeong, J.-Y., Berg, D. E.
(2000). Mouse-Colonizing Helicobacter pylori SS1 Is Unusually Susceptible to Metronidazole Due to Two Complementary Reductase Activities. Antimicrob. Age